Rituximab (500 mg)

admin — Wed, 18 Feb 2026 10:55:10 +0000

Overview: Erlotinib 150 mg Tablets contain Erlotinib (150 mg) and are prescribed as an oral targeted anticancer medicine used in the treatment of epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) and certain pancreatic cancers by inhibiting cancer cell growth signaling pathways. Key Benefits: – Targets EGFR pathways to slow tumor progression in NSCLC – Oral dosing for convenient outpatient treatment – Also used in select pancreatic cancer protocols Composition: Erlotinib (150 mg) How It Works: Erlotinib blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), preventing downstream signaling that drives cancer cell proliferation and survival, helping to slow tumor growth. Usage Instructions: – Take exactly as directed by your oncologist – Swallow the tablet whole with water, with or without food – Do not crush or chew the tablet Side Effects: – Rash, diarrhea, nausea – Fatigue, loss of appetite – Rare liver enzyme elevations Precautions: – Monitor liver function and skin reactions during treatment – Not recommended during pregnancy or breastfeeding unless advised by a physician – Inform your doctor of all current medications Storage Instructions: – Store below 30°C in a cool, dry place away from moisture and light Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.

Erlotinib 150mg – Globalstar International

Rituximab (500 mg)